A new study shows that the BRAF inhibitor vemurafenib may induce partial 
responses and stable disease in patients with papillary thyroid cancer that has 
become refractory to radioactive iodine. However, the drug led to a variety of 
serious adverse events in roughly 65% of patients, including the development of 
some squamous cell carcinomas.